{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:30:02Z","timestamp":1789831802169,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00280-019-03907-1","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T16:02:34Z","timestamp":1563552154000},"page":"749-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects"],"prefix":"10.1007","volume":"84","author":[{"given":"Vassilios","family":"Aslanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Ouatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Bharathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Avigdor","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gadbaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"3907_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/leu.2013.205","volume":"28","author":"T Zhou","year":"2014","unstructured":"Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, Hantschel O (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28:404\u2013407. \n                    https:\/\/doi.org\/10.1038\/leu.2013.205","journal-title":"Leukemia"},{"key":"3907_CR2","unstructured":"US Food and Drug Administration (2011) Jakafi prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf\n                    \n                  . Accessed 22 Feb 2018"},{"key":"3907_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24:133\u2013145. \n                    https:\/\/doi.org\/10.1016\/j.cytogfr.2013.01.004","journal-title":"Cytokine Growth Factor Rev"},{"key":"3907_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","volume":"83","author":"MM Seavey","year":"2012","unstructured":"Seavey MM, Dobrzanski P (2012) The many faces of Janus kinase. Biochem Pharmacol 83:1136\u20131145. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2011.12.024","journal-title":"Biochem Pharmacol"},{"key":"3907_CR5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN (2013) JAK\/STAT signaling in hematological malignancies. Oncogene 32:2601\u20132613. \n                    https:\/\/doi.org\/10.1038\/onc.2012.347","journal-title":"Oncogene"},{"key":"3907_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","volume":"1","author":"M Furqan","year":"2013","unstructured":"Furqan M, Mukhi N, Lee B, Liu D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1:5. \n                    https:\/\/doi.org\/10.1186\/2050-7771-1-5","journal-title":"Biomark Res"},{"key":"3907_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"3907_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:1701\u20131707. \n                    https:\/\/doi.org\/10.1038\/leu.2016.148","journal-title":"Leukemia"},{"key":"3907_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"3907_CR10","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"AD Shilling","year":"2010","unstructured":"Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, Yeleswaram S (2010) Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos 38:2023\u20132031. \n                    https:\/\/doi.org\/10.1124\/dmd.110.033787","journal-title":"Drug Metab Dispos"},{"key":"3907_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/jcph.102","volume":"53","author":"X Chen","year":"2013","unstructured":"Chen X, Williams WV, Sandor V, Yeleswaram S (2013) Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol 53:721\u2013730. \n                    https:\/\/doi.org\/10.1002\/jcph.102","journal-title":"J Clin Pharmacol"},{"key":"3907_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51:1644\u20131654. \n                    https:\/\/doi.org\/10.1177\/0091270010389469","journal-title":"J Clin Pharmacol"},{"key":"3907_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52:809\u2013818. \n                    https:\/\/doi.org\/10.1177\/0091270011405663","journal-title":"J Clin Pharmacol"},{"key":"3907_CR14","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0042","author":"K Umehara","year":"2019","unstructured":"Umehara K, Huth F, Jin Y, Schiller H, Aslanis V, Heimbach T, He H (2019) Drug\u2013drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug Metab Pers Ther. \n                    https:\/\/doi.org\/10.1515\/dmpt-2018-0042","journal-title":"Drug Metab Pers Ther"},{"key":"3907_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cpt.30","volume":"97","author":"JG Shi","year":"2015","unstructured":"Shi JG, Fraczkiewicz G, Williams WV, Yeleswaram S (2015) Predicting drug\u2013drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clin Pharmacol Ther 97:177\u2013185. \n                    https:\/\/doi.org\/10.1002\/cpt.30","journal-title":"Clin Pharmacol Ther"},{"key":"3907_CR16","unstructured":"US Food and Drug Administration (2011) Fluconazole for oral suspension. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s051lbl.pdf\n                    \n                  . Accessed 25 Feb 2018"},{"key":"3907_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:737\u2013779. \n                    https:\/\/doi.org\/10.1007\/s15010-017-1042-z","journal-title":"Infection"},{"key":"3907_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","volume":"48","author":"MD Johnson","year":"2004","unstructured":"Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH (2004) Combination antifungal therapy. Antimicrob Agents Chemother 48:693\u2013715. \n                    https:\/\/doi.org\/10.1128\/AAC.48.3.693-715.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"3907_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.13181\/mji.v20i3.453","volume":"20","author":"J Susilo","year":"2011","unstructured":"Susilo J, Setiawati A, Darmansjah I, Indarti J, Kusuma F (2011) Low-dose ketoconazole-fluconazole combination versus fluconazole in single doses for the treatment of vaginal candidiasis. Med J Indones 20:205\u2013211. \n                    https:\/\/doi.org\/10.13181\/mji.v20i3.453","journal-title":"Med J Indones"},{"key":"3907_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cpdd.71","volume":"3","author":"P Gupta","year":"2014","unstructured":"Gupta P, Chow V, Wang R, Kaplan I, Chan G, Alvey C, Ni G, Ndongo MN, LaBadie RR, Krishnaswami S (2014) Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin Pharmacol Drug Dev 3:72\u201377. \n                    https:\/\/doi.org\/10.1002\/cpdd.71","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3907_CR21","unstructured":"US Food and Drug Administration (2017) Clinical drug interaction studies\u2014study design, data analysis, and clinical implications. Guidance for industry. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm292362.pdf\n                    \n                  . Accessed 26 Feb 2018"},{"key":"3907_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","volume":"33","author":"D Debruyne","year":"1997","unstructured":"Debruyne D (1997) Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33:52\u201377. \n                    https:\/\/doi.org\/10.2165\/00003088-199733010-00005","journal-title":"Clin Pharmacokinet"},{"key":"3907_CR23","unstructured":"European Commission. Jakavi\u2014summary of product characteristics. \n                    https:\/\/ec.europa.eu\/health\/documents\/community-register\/2012\/20120823123254\/anx_123254_en.pdf\n                    \n                  . Accessed 26 Feb 2018"},{"key":"3907_CR24","unstructured":"US Food and Drug Administration. Jakafi prescribing information (revised 2017). \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf\n                    \n                  . Accessed 26 Feb 2018"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03907-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03907-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03907-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:10:31Z","timestamp":1595027431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03907-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3907"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03907-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"29 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FH, TO, SB, AB, WZ, and BG are all employees of Novartis. VA and KU were employed with Novartis during the study period. BG, FH and TO own stocks of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}